The Management of Acute Hypertension in Patients With Renal Dysfunction: Labetalol or Nicardipine?. Issue 4 (July 2014)
- Record Type:
- Journal Article
- Title:
- The Management of Acute Hypertension in Patients With Renal Dysfunction: Labetalol or Nicardipine?. Issue 4 (July 2014)
- Main Title:
- The Management of Acute Hypertension in Patients With Renal Dysfunction: Labetalol or Nicardipine?
- Authors:
- Varon, Joseph
Soto-Ruiz, Karina M.
Baumann, Brigitte M.
Borczuk, Pierre
Cannon, Chad M.
Chandra, Abhinav
Cline, David Martin
Diercks, Deborah B.
Hiestand, Brian
Hsu, Amy
Jois-Bilowich, Preeti
Kaminski, Brian
Levy, Phillip
Nowak, Richard M.
Schrock, Jon W.
Peacock, W. Frank - Abstract:
- Abstract: Study Objectives: To compare the safety and efficacy of US Food and Drug Administration (FDA)-recommended doses of labetalol and nicardipine for hypertension (HTN) management in a subset of patients with renal dysfunction (RD).Design: Randomized, open label, multicenter prospective clinical trial.Setting: Thirteen United States tertiary care emergency departments.Patients or Participants: Subgroup analysis of the Evaluation of IV Cardene (Nicardipine) and Labetalol Use in the Emergency Department (CLUE) clinical trial. The subjects were 104 patients with RD (ie, creatinine clearance < 75 mL/min) who presented to the emergency department with a systolic blood pressure (SBP) ≥ 180 mmHg on 2 consecutive readings and for whom the emergency physician felt intravenous antihypertensive therapy was desirable.Interventions: The FDA recommended doses of either labetalol or nicardipine for HTN management.Measurements: The number of patients achieving the physician's predefined target SBP range within 30 minutes of treatment.Results: Patients treated with nicardipine were within target range more often than those receiving labetalol (92% vs 78%, P = 0.046). On 6 SBP measures, patients treated with nicardipine were more likely to achieve the target range on either 5 or all 6 readings than were patients treated with labetalol (46% vs 25%, P = 0.024). Labetalol patients were more likely to require rescue medication (27% vs 17%, P = 0.020). Adverse events thought to be related toAbstract: Study Objectives: To compare the safety and efficacy of US Food and Drug Administration (FDA)-recommended doses of labetalol and nicardipine for hypertension (HTN) management in a subset of patients with renal dysfunction (RD).Design: Randomized, open label, multicenter prospective clinical trial.Setting: Thirteen United States tertiary care emergency departments.Patients or Participants: Subgroup analysis of the Evaluation of IV Cardene (Nicardipine) and Labetalol Use in the Emergency Department (CLUE) clinical trial. The subjects were 104 patients with RD (ie, creatinine clearance < 75 mL/min) who presented to the emergency department with a systolic blood pressure (SBP) ≥ 180 mmHg on 2 consecutive readings and for whom the emergency physician felt intravenous antihypertensive therapy was desirable.Interventions: The FDA recommended doses of either labetalol or nicardipine for HTN management.Measurements: The number of patients achieving the physician's predefined target SBP range within 30 minutes of treatment.Results: Patients treated with nicardipine were within target range more often than those receiving labetalol (92% vs 78%, P = 0.046). On 6 SBP measures, patients treated with nicardipine were more likely to achieve the target range on either 5 or all 6 readings than were patients treated with labetalol (46% vs 25%, P = 0.024). Labetalol patients were more likely to require rescue medication (27% vs 17%, P = 0.020). Adverse events thought to be related to either treatment group were not reported in the 30-minute active study period, and patients had slower heart rates at all time points after 5 minutes ( P < 0.01).Conclusions: In severe HTN with RD, nicardipine-treated patients are more likely to reach a target blood pressure range within 30 minutes than are patients receiving labetalol.Clinical Implications: Within 30 minutes of administration, nicardipine is more efficacious than labetalol for acute blood pressure control in patients with RD. … (more)
- Is Part Of:
- Postgraduate medicine. Volume 126:Issue 4(2014)
- Journal:
- Postgraduate medicine
- Issue:
- Volume 126:Issue 4(2014)
- Issue Display:
- Volume 126, Issue 4 (2014)
- Year:
- 2014
- Volume:
- 126
- Issue:
- 4
- Issue Sort Value:
- 2014-0126-0004-0000
- Page Start:
- 124
- Page End:
- 130
- Publication Date:
- 2014-07
- Subjects:
- acute disease -- antihypertensive agents/therapeutic use -- hypertension/drug therapy -- kidney diseases/drug therapy
Medicine -- Periodicals
Medicine -- Periodicals
Medicine
Periodicals
610.5 - Journal URLs:
- http://www.postgradmed.com/journal.htm ↗
http://www.tandfonline.com/toc/ipgm20/current#.VjJrC_6FOUk ↗
http://www.tandfonline.com/ ↗ - DOI:
- 10.3810/pgm.2014.07.2790 ↗
- Languages:
- English
- ISSNs:
- 0032-5481
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 9216.xml